Use of 2 anti-sparc antibodies to predict response to chemotherapy
AssigneeAbraxis BioScience, LLC
InventorsVuong Trieu, Neil Desai, Daniel Knauer
Life of this patent
Estimating the term…
Abstract
The invention provides anti-SPARC antibody-based techniques for predicting a response to chemotherapy.
Claims16
A method for predicting the response of a tumor in an animal to a chemotherapeutic regimen comprising:
- (a) applying a first anti-SPARC antibody to a histologic section of the tumor, wherein the first anti-SPARC antibody preferentially immunostains SPARC in tumor cells;
- (b) applying a second anti-SPARC antibody to the histologic section of (a) or a second histologic section of the tumor, wherein the second anti-SPARC antibody preferentially immunostains SPARC in fibroblasts;
- and
- (c) predicting a positive response to the chemotherapeutic regimen if the first anti-SPARC antibody and the second anti-SPARC antibody immunostain the histologic section or sections.
A method for predicting the response of a tumor in an animal to a chemotherapeutic regimen comprising:
- (a) applying a first anti-SPARC antibody to a histologic section of the tumor, wherein the first anti-SPARC antibody preferentially immunostains SPARC in tumor cells;
- (b) applying a second anti-SPARC antibody to the histologic section of (a) or a second histologic section of the tumor, wherein the second anti-SPARC antibody preferentially immunostains SPARC in fibroblasts;
- and
- (c) predicting a positive response to the chemotherapeutic regimen if the second anti-SPARC antibody immunostains the histologic section or sections.
A method of treating a tumor in an animal with a chemotherapeutic regimen comprising:
- (a) applying a first anti-SPARC antibody to a histologic section of the tumor, wherein the first anti-SPARC antibody preferentially immunostains SPARC in tumor cells;
- (b) applying a second anti-SPARC antibody to the histologic section of (a) or a second histologic section of the tumor, wherein the second anti-SPARC antibody preferentially immunostains SPARC in fibroblasts;
- and
- (c) administering the chemotherapeutic regimen if the first anti-SPARC antibody and the second anti-SPARC antibody immunostain the histologic section or sections.
A method for predicting the response of a tumor in an animal to a chemotherapeutic regimen comprising:
- (a) applying an anti-SPARC antibody to a histologic section of the tumor, wherein the anti-SPARC antibody recognizes a SPARC epitope recognized by monoclonal antibody MAB941;
- (b) predicting a poor response to the chemotherapeutic regimen if the anti-SPARC antibody immunostains the histologic section or sections.
A method for predicting the response of a tumor in an animal to a chemotherapeutic regimen comprising:
- (a) applying an anti-SPARC antibody to the histologic section of (a) or a second histologic section of the tumor, wherein the second antibody recognizes an immunodominant SPARC epitope recognized by polyclonal antibody AF941;
- and
- (b) predicting a positive response to the chemotherapeutic regimen if the anti-SPARC antibody immunostains the histologic section or sections.
-24. (canceled)
Dependencies are inferred from the claim text.